Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59.
Earnest L, Ruiz DF, Edeling MA, Montoya JC, Yap AHY, Wong CY, Holz LE, Gras S, Collett S, Cooney JP, Davidson KC, Grimley SL, Purcell DFJ, Roberts J, Mumford J, Tan CW, Wang LF, Godfrey DI, Frieman M, Hans D, Vincan E, Anderson DE, Subbarao K, Pellegrini M, Mackenzie JM, Rockman S, Heath WR, Torresi J.
Earnest L, et al. Among authors: rockman s.
NPJ Vaccines. 2026 Jan 17;11(1):34. doi: 10.1038/s41541-025-01355-y.
NPJ Vaccines. 2026.
PMID: 41547962
Free PMC article.